CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs)

J Natl Compr Canc Netw. 2024 Apr 5;22(2.5):CLO24-079. doi: 10.6004/jnccn.2023.7228.NO ABSTRACTPMID:38580254 | DOI:10.6004/jnccn.2023.7228

Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 5, 2024 Category: Cancer & Oncology Authors: Yazan Madanat Michael R Savona Mikkael A Sekeres Uwe Platzbecker Valeria Santini Pierre Fenaux Maria Diez-Campelo David Valc árcel Tymara Berry Souria Dougherty Sheetal Shah Libo Sun Ying Wan Fei Huang Shyamala Navada Rami S Komrokji Amer M Zeidan Source Type: research